UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 435

Sortiert nach

Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling

MedChemComm, 2017-03, Vol.8 (3), p.534-550

2017

Volltextzugriff (PDF)

Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: Combined analysis from phase I and II studies

Annals of oncology, 2018-10, Vol.29, p.viii359-viii360

2018

Volltextzugriff (PDF)

Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1

Hematological oncology, 2023-06, Vol.41 (S2), p.560-562

2023

Volltextzugriff (PDF)

S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT

HemaSphere, 2022-06, Vol.6, p.60-61

2022

Volltextzugriff (PDF)

COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA

Hematological oncology, 2019-06, Vol.37 (S2), p.399-400

2019

Volltextzugriff (PDF)

CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA FOLLOWING RETREATMENT WITH SECOND‐LINE RITUXIMAB‐CONTAINING CHEMOTHERAPY

Hematological oncology, 2019-06, Vol.37 (S2), p.397-398

2019

Volltextzugriff (PDF)

EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB

Hematological oncology, 2019-06, Vol.37 (S2), p.387-389

2019

Volltextzugriff (PDF)

SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS‐1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA

Hematological oncology, 2019-06, Vol.37 (S2), p.389-390

2019

Volltextzugriff (PDF)

COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)

Hematological oncology, 2017-06, Vol.35 (S2), p.119-120

2017

Volltextzugriff (PDF)

Modified Corneosurfametry as a new accelerated high-throughput ex vivo methodology for predicting cleanser effects towards human skin

International journal of cosmetic science, 2016-04, Vol.38 (2), p.178-186

2016

Volltextzugriff (PDF)

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

American journal of hematology, 2020-04, Vol.95 (4), p.362-371

2020

Volltextzugriff (PDF)

CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA FOLLOWING RETREATMENT WITH SECOND‐LINE RITUXIMAB‐CONTAINING CHEMOTHERAPY

Hematological oncology, 2019-06, Vol.37 (S2), p.397-398

2019

Volltextzugriff (PDF)

EP06.05-06 Distant Metastasis Pattern and Baseline Clinicopathological Features from a Real-World KRAS G12C Mutant Cohort of Advanced NSCLC Patients

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S495-S496

2023

Volltextzugriff (PDF)

Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modellingThe authors declare no competing interests

2017-03

Volltextzugriff (PDF)

Protein–ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling† †The authors declare no competing interests

MedChemComm, 2017-01, Vol.8 (3), p.534-550

2017

Volltextzugriff (PDF)

86P Artificial intelligence tools to predict early progression of non-small cell lung cancer patients treated with immunotherapy: Preliminary evidence from a single-centre experience of black-box and white-box models pairing

ESMO open, 2024-03, Vol.9, p.102665, Article 102665

2024

Volltextzugriff (PDF)

Trends in State Regulation of Assisted Living

Generations (San Francisco, Calif.), 2008-10, Vol.32 (3), p.67-70

Mollica, Robert

2008

Volltextzugriff (PDF)

Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study

Annals of oncology, 2017-09, Vol.28, p.v357-v357

2017

Volltextzugriff (PDF)

No Association Between Telomere Length and Blood Cell Counts in Elderly Individuals

The journals of gerontology. Series A, Biological sciences and medical sciences, 2009-09, Vol.64A (9), p.965-967

2009

Volltextzugriff (PDF)

Proteolytic inactivation of ADAMTS13 by thrombin and plasmin

Blood, 2005-02, Vol.105 (3), p.1085-1093

2005

Volltextzugriff (PDF)

PS1254 CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA AFTER RETREATMENT WITH SECOND‐LINE RITUXIMAB‐CONTAINING CHEMOTHERAPY

HemaSphere, 2019-06, Vol.3 (S1), p.572-573

2019

Volltextzugriff (PDF)

Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein

The Journal of biological chemistry, 2003-11, Vol.278 (48), p.48146-48153

2003

Volltextzugriff (PDF)

Redox regulation of cyclophilin A by glutathionylation

Proteomics (Weinheim), 2006-02, Vol.6 (3), p.817-825

2006

Volltextzugriff (PDF)

MANAGED CARE AND ASSISTED LIVING: TRENDS AND FUTURE PROSPECTS

Journal of health and human services administration, 1998-01, Vol.20 (3), p.264-280

MOLLICA, ROBERT L.

1998

Volltextzugriff (PDF)

Digital twins: a new paradigm in oncology in the era of big data

ESMO Real World Data and Digital Oncology, 2024-09, Vol.5, p.100056, Article 100056

2024

Volltextzugriff (PDF)

1 – 25 von 435

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(349)
Mit Volltextzugriff
(316)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling

Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: Combined analysis from phase I and II studies

Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1

S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT

COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA

CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA FOLLOWING RETREATMENT WITH SECOND‐LINE RITUXIMAB‐CONTAINING CHEMOTHERAPY

EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB

SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS‐1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA

COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)

Modified Corneosurfametry as a new accelerated high-throughput ex vivo methodology for predicting cleanser effects towards human skin

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA FOLLOWING RETREATMENT WITH SECOND‐LINE RITUXIMAB‐CONTAINING CHEMOTHERAPY

EP06.05-06 Distant Metastasis Pattern and Baseline Clinicopathological Features from a Real-World KRAS G12C Mutant Cohort of Advanced NSCLC Patients

Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modellingThe authors declare no competing interests

Protein–ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling† †The authors declare no competing interests

86P Artificial intelligence tools to predict early progression of non-small cell lung cancer patients treated with immunotherapy: Preliminary evidence from a single-centre experience of black-box and white-box models pairing

Trends in State Regulation of Assisted Living

Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study

No Association Between Telomere Length and Blood Cell Counts in Elderly Individuals

Proteolytic inactivation of ADAMTS13 by thrombin and plasmin

PS1254 CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA AFTER RETREATMENT WITH SECOND‐LINE RITUXIMAB‐CONTAINING CHEMOTHERAPY

Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein

Redox regulation of cyclophilin A by glutathionylation

MANAGED CARE AND ASSISTED LIVING: TRENDS AND FUTURE PROSPECTS

Digital twins: a new paradigm in oncology in the era of big data

Suchergebnisse filtern